These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
170 related articles for article (PubMed ID: 23996162)
61. Pathological evaluation of neoadjuvant chemotherapy in advanced gastric cancer. Hu SB; Liu CH; Wang X; Dong YW; Zhao L; Liu HF; Cao Y; Zhong DR; Liu W; Li YL; Gao WS; Bai CM; Shang ZH; Li XY World J Surg Oncol; 2019 Jan; 17(1):3. PubMed ID: 30606195 [TBL] [Abstract][Full Text] [Related]
62. Glutathione-S-transferase P1, T1 and M1 genetic polymorphisms in neoadjuvant-treated locally advanced gastric cancer: GSTM1-present genotype is associated with better prognosis in completely resected patients. Ott K; Lordick F; Becker K; Ulm K; Siewert J; Höfler H; Keller G Int J Colorectal Dis; 2008 Aug; 23(8):773-82. PubMed ID: 18443805 [TBL] [Abstract][Full Text] [Related]
63. 18F-FDG PET-Derived Tumor Blood Flow Changes After 1 Cycle of Neoadjuvant Chemotherapy Predicts Outcome in Triple-Negative Breast Cancer. Humbert O; Riedinger JM; Vrigneaud JM; Kanoun S; Dygai-Cochet I; Berriolo-Riedinger A; Toubeau M; Depardon E; Lassere M; Tisserand S; Fumoleau P; Brunotte F; Cochet A J Nucl Med; 2016 Nov; 57(11):1707-1712. PubMed ID: 27103025 [TBL] [Abstract][Full Text] [Related]
64. Accuracy and reproducibility of 3D-CT measurements for early response assessment of chemoradiotherapy in patients with oesophageal cancer. van Heijl M; Phoa SS; van Berge Henegouwen MI; Omloo JM; Mearadji BM; Sloof GW; Bossuyt PM; Hulshof MC; Richel DJ; Bergman JJ; Ten Kate FJ; Stoker J; van Lanschot JJ Eur J Surg Oncol; 2011 Dec; 37(12):1064-71. PubMed ID: 21944048 [TBL] [Abstract][Full Text] [Related]
65. Diagnostic accuracy of T and N stages with endoscopy, stomach protocol CT, and endoscopic ultrasonography in early gastric cancer. Ahn HS; Lee HJ; Yoo MW; Kim SG; Im JP; Kim SH; Kim WH; Lee KU; Yang HK J Surg Oncol; 2009 Jan; 99(1):20-7. PubMed ID: 18937292 [TBL] [Abstract][Full Text] [Related]
66. Prediction of neoadjuvant radiation chemotherapy response and survival using pretreatment [(18)F]FDG PET/CT scans in locally advanced rectal cancer. Bang JI; Ha S; Kang SB; Lee KW; Lee HS; Kim JS; Oh HK; Lee HY; Kim SE Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):422-31. PubMed ID: 26338180 [TBL] [Abstract][Full Text] [Related]
67. Temporal validation of metabolic nodal response of esophageal cancer to neoadjuvant chemotherapy as an independent predictor of unresectable disease, survival, and recurrence. Findlay JM; Dickson E; Fiorani C; Bradley KM; Mukherjee S; Gillies RS; Maynard ND; Middleton MR Eur Radiol; 2019 Dec; 29(12):6717-6727. PubMed ID: 31278574 [TBL] [Abstract][Full Text] [Related]
68. Volume-based metabolic tumor response to neoadjuvant chemotherapy is associated with an increased risk of recurrence in breast cancer. Hyun SH; Ahn HK; Park YH; Im YH; Kil WH; Lee JE; Nam SJ; Cho EY; Choi JY Radiology; 2015 Apr; 275(1):235-44. PubMed ID: 25496075 [TBL] [Abstract][Full Text] [Related]
69. Accuracy of positron emission tomography/computed tomography and clinical assessment in the detection of complete rectal tumor regression after neoadjuvant chemoradiation: long-term results of a prospective trial (National Clinical Trial 00254683). Perez RO; Habr-Gama A; Gama-Rodrigues J; Proscurshim I; Julião GP; Lynn P; Ono CR; Campos FG; Silva e Sousa AH; Imperiale AR; Nahas SC; Buchpiguel CA Cancer; 2012 Jul; 118(14):3501-11. PubMed ID: 22086847 [TBL] [Abstract][Full Text] [Related]
70. [Efficacy of neoadjuvant chemotherpy in patients with locally advanced gastric cancer]. Wang Y; Liu TS; Zhuang RY; Cui YH; Wang ZM; Yu YY; Hou J; Sun YH; Shen KT; Shen ZB Zhonghua Wei Chang Wai Ke Za Zhi; 2013 Feb; 16(2):166-9. PubMed ID: 23446480 [TBL] [Abstract][Full Text] [Related]
71. 18F-FDG PET/CT to Predict Response to Neoadjuvant Chemotherapy and Prognosis in Inflammatory Breast Cancer. Champion L; Lerebours F; Alberini JL; Fourme E; Gontier E; Bertrand F; Wartski M J Nucl Med; 2015 Sep; 56(9):1315-21. PubMed ID: 26159587 [TBL] [Abstract][Full Text] [Related]
72. Utility of MRI and PET/CT after neoadjuvant chemotherapy in breast cancer patients: correlation with pathological response grading system based on tumor cellularity. Kim T; Kang DK; An YS; Yim H; Jung YS; Kim KS; Kang SY; Kim TH Acta Radiol; 2014 May; 55(4):399-408. PubMed ID: 23963151 [TBL] [Abstract][Full Text] [Related]
73. Serial imaging using [18F]Fluorodeoxyglucose positron emission tomography and histopathologic assessment in predicting survival in a population of surgically resectable distal oesophageal and gastric adenocarcinoma following neoadjuvant therapy. Manoharan V; Lee S; Chong S; Yap J; Coupe N; Wilson R; Merrett N; Ng W; Lin M Ann Nucl Med; 2017 May; 31(4):315-323. PubMed ID: 28299585 [TBL] [Abstract][Full Text] [Related]
74. Perfusion CT - A novel quantitative and qualitative imaging biomarker in gastric cancer. Kruk-Bachonko J; Krupski W; Czechowski M; Kurys-Denis E; Mądro P; Sierocińska-Sawa J; Dąbrowski A; Wallner G; Skoczylas T Eur J Radiol; 2017 Oct; 95():399-408. PubMed ID: 28987697 [TBL] [Abstract][Full Text] [Related]
75. CT evaluation after neoadjuvant FOLFIRINOX chemotherapy for borderline and locally advanced pancreatic adenocarcinoma. Wagner M; Antunes C; Pietrasz D; Cassinotto C; Zappa M; Sa Cunha A; Lucidarme O; Bachet JB Eur Radiol; 2017 Jul; 27(7):3104-3116. PubMed ID: 27896469 [TBL] [Abstract][Full Text] [Related]
76. Role of Akimoto E; Kadoya T; Kajitani K; Emi A; Shigematsu H; Ohara M; Masumoto N; Okada M Clin Breast Cancer; 2018 Feb; 18(1):45-52. PubMed ID: 28993056 [TBL] [Abstract][Full Text] [Related]
77. Relationship of clinical and pathologic response to neoadjuvant chemotherapy and outcome of locally advanced breast cancer. Gajdos C; Tartter PI; Estabrook A; Gistrak MA; Jaffer S; Bleiweiss IJ J Surg Oncol; 2002 May; 80(1):4-11. PubMed ID: 11967899 [TBL] [Abstract][Full Text] [Related]